|
|
Vaccine Detail
|
T-glycosylated MUC1–YSYFPSV–Pam₃CysSer Tricomponent Vaccine |
| Vaccine Information |
- Vaccine Name: T-glycosylated MUC1–YSYFPSV–Pam₃CysSer Tricomponent Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Wilkinson et al., 2011)
- Immunization Route: Intramuscular injection (i.m.)
- Description: A tricomponent synthetic cancer vaccine combining per-T-glycosylated MUC1 VNTR peptide (20-mer: GVTSAPDTRPAPGSTAPPAH) as B-cell epitope, tetanus toxoid helper T-cell epitope (YSYFPSV), and Pam?CysSer TLR2 agonist, covalently linked via ethylene glycol spacers. Immunization in C57BL/6 mice (20 ?g) without external adjuvant elicited high IgG antibody titers (54,600), 21-fold higher than Tn-glycosylated variant. Antibodies demonstrated tumor selectivity, binding MCF7 breast cancer cells (22-48%) but not native MUC1 from normal tissue. Absence of IgM indicated establishment of immunological memory (Wilkinson et al., 2011).
|
| Host Response |
|
|
| References |
Wilkinson et al., 2011: Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angewandte Chemie (International ed. in English). 2011; 50(7); 1635-1639. [PubMed: 21308921].
|
|
